EFLOXATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H16O5
Molecular Weight	324.3273
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)COC1=CC2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3

InChI

InChIKey=ZVXBAHLOGZCFTP-UHFFFAOYSA-N

InChI=1S/C19H16O5/c1-2-22-19(21)12-23-14-8-9-15-16(20)11-17(24-18(15)10-14)13-6-4-3-5-7-13/h3-11H,2,12H2,1H3

HIDE SMILES / InChI

Molecular Formula	C19H16O5
Molecular Weight	324.3273
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13816307
Curator's Comment: description was created based on several sources, including, http://www.recordati.com/en/about_us/history/

Efloxate is a coronary vasodilator developed in 1959 in Italy by Recordati and used for the treatment of angina pectoris. The drug is no longer marketed.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 110 Sources: http://www.ncbi.nlm.nih.gov/pubmed/13816307	Primary		Approved 8583	RECORDIL Approved Use Unknown

Doses

Dose	Population	Adverse events
60 mg 1 times / day multiple, oral Highest studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: http://www.ncbi.nlm.nih.gov/pubmed/13816307	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: http://www.ncbi.nlm.nih.gov/pubmed/13816307	Sources: http://www.ncbi.nlm.nih.gov/pubmed/13816307

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 CYP19A1 429 UMAT 30	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144206729	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1347076#sid=26729810	no
UMAT 30	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/602162#sid=26729810	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=144206728	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/720551#sid=26729810

PubMed

Title	Date	PubMed
[Mutagenesis of efloxate tested in vitro and in vivo].	1985-03	3896262
[The effect of 4'-methylrecordil on coronary artery blood flow and experimental myocardial infarction in rabbits].	1982-07	7180478
[Clinical research on the therapeutic efficacy and tolerance of long-acting efloxate in angina pectoris].	1977-08-15	334448
A clinical trial of penta-erythritol tetranitrate, a khellin derivative (recordil), and iproniazid in angina of effort.	1959-07	13816307
[Ethyl-7-hydroxyaceto-flavone (recordil) in the therapy of angina pectoris and its effects on hemodynamics and renal function].	1959	13629509

Sample Use Guides

In Vivo Use Guide

One 15 mg. tablet a day, gradually increased over 7 to 8 days to 3 or 4 tablets daily (45 to 60 mg.), and given over a period of at least three months.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:22:53 GMT 2025` Edited by `admin` on `Mon Mar 31 18:22:53 GMT 2025`
Record UNII	CZU6V3902K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EFLOXATE [JAN]

Preferred Name

English

EFLOXATE

Official Name

English

ETHYL-((4-OXO-2-PHENYL-4H-1-BENZOPYRAN-7-YL)OXY) ACETATE

Systematic Name

English

Efloxate [WHO-DD]

Common Name

English

efloxate [INN]

Common Name

English

NSC-758891

Code

English

EFLOXATE [MI]

Common Name

English

EFLOXATE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707